Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
05/23/2022 - 08:00 AM
NASHVILLE, Tenn. --(BUSINESS WIRE)--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference , taking place June 6-9 , in Chicago . Chief Executive Officer, Mark Foley , is scheduled to present on Monday, June 6 , at 2:00 p.m. CT / 3:00 p.m. ET .
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com . The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Revance Therapeutics, Inc.
Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at www.revance.com .
"Revance Therapeutics " and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA .
BOTOX® is a registered trademark of Allergan, Inc.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220523005368/en/
Investors
Revance Therapeutics, Inc. :
Jessica Serra , 626-589-1007
jessica.serra@revance.com
Gilmartin Group, LLC .:
Laurence Watts , 619-916-7620
laurence@gilmartinir.com
Media
Revance Therapeutics, Inc. :
Sara Fahy , 949-887-4476
sfahy@revance.com
Source: Revance Therapeutics, Inc.
RVNC Rankings
#5006 Ranked by Stock Gains
RVNC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Newark
About RVNC
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
